Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug ...

In recent weeks, Health and Human Services Secretary Robert F. Kennedy Jr. has said that "very, very strong studies" link ...

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by ...

With the acquisition of Theravia, Norgine will now have six core products in its rare disease portfolio (PEDMARQSI ®, eflornithine, mavorixafor, AGILUS ®, SIKLOS ® and ORPHACOL ®) thereby comprising a ...

What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the new publication[2] of positive in vivo data, in the journal Diabetes, Metabolic Syndrome ...

Avant Technologies, Inc. ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using ...

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 16, 2025 /PRNewswire/ -- Equity Insider News Commentary - The potential ...